ArticleLeukemia2017
Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2026Review
- Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes.Bone marrow transplantation · 2026Article
- Teclistamab for heavily pretreated relapsed/refractory POEMS syndrome.Haematologica · 2026Article
- POEMS syndrome: diagnosis, treatments, and outcomes.Hematology. American Society of Hematology. Education Program · 2025Article
- [Chinese expert consensus on the diagnosis and treatment of POEMS syndrome (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature.Frontiers in oncology · 2025Article
- Review
- What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?Haematologica · 2024Article
- A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.Journal of Korean medical science · 2024Article
- Case report: DKRd regimen in the treatment of newly diagnosed POEMS syndrome and literature review.Frontiers in oncology · 2024Article
- Case report: Atypical POEMS syndrome without polyneuropathy, complicated by borderline TAFRO syndrome.Frontiers in medicine · 2024Article
- Treatment and outcome of second-line therapy for POEMS syndrome after autologous stem cell transplantation.Bone marrow transplantation · 2023Article
- Comprehensive Diagnosis and Management of POEMS Syndrome.HemaSphere · 2022Review
- Article
- Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.Internal medicine (Tokyo, Japan) · 2022Article
- Not the final diagnosis: from Addison's disease to POEMS syndrome: a case report and literature review.The Journal of international medical research · 2021Review
- Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome.Bone marrow transplantation · 2021Article
- [How I diagnose and treat POEMS syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) is a rare plasma cell dyscrasia sometimes treated with a haematopoietic cell autotransplant. We analyzed data from 138 subjects with newly diagnosed POEMS syndrome receiving a autotransplant at our center. Thirty-two subjects with severe end-organ dysfunction ineligible for immediate autotransplant received pretransplant therapy, which made a subsequent autotransplant feasible. Pretransplant therapy resulted in vascular endothelial growth factor (VEGF) remissions in 15 (47%). Thirty-three transplant recipients (24%) had early posttransplant complications. Risk factors for these complications identified through multivariate analysis included age >50 years (odds ratio (OR) 2.79, 95% confidence interval (CI) 1.09-7.14; P=0.033), time from symptom onset to transplant >5 years (OR 4.71, 95% CI 1.10-20.18; P=0.037) and pleural effusion (OR 3.39, 95% CI 1.26-9.12; P=0.016). Subjects receiving pretransplant therapy had fewer early complications than those who did not (OR 0.17, 95% CI 0.04-0.71; P=0.015), especially in subjects with a VEGF remission (OR 0.05, 95% CI 0.01-0.49; P=0.010). Autotransplants resulted in hematological remission in 60 (50%), VEGF remissions in 76 (72%) and improvements in other organ functions (65-90%). The 5-year progression-free survival (PFS) and overall survival were 76% (95% CI 64-84%) and 94% (95% CI 87-97%), respectively. Hematological (5-year PFS 83 vs 66%, P=0.008), VEGF (5-year PFS 79 vs 57%, P=0.021) remissions and especially both (5-year PFS 95 vs 61%, P=0.004) were associated with better PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.